Search Results for: GLUT1

Patients Live Twice as Long with Less of this Biomarker for Pleural Mesothelioma
| | |

Patients Live Twice as Long with Less of this Biomarker for Pleural Mesothelioma

ByAlex Strauss

An enzyme that helps mop up the products of cellular oxidation might also serve as a powerful biomarker for pleural mesothelioma. People with the lowest levels of this enzyme  survived longer with mesothelioma than those with higher levels. Glutathione peroxidase-1 (GPX-1) is an enzyme found in all cells. It helps keep toxins from building up inside cells. It also helps regulate certain cellular processes.   But there is also evidence that GPX-1 may play a role in the development of cancer. Researchers in Egypt recently discovered that pleural mesothelioma tumors have more GPX-1 than the healthy tissue around them. The less they have, the better the prognosis.  The findings suggest that GPX-1 could be a useful biomarker for pleural mesothelioma.  Mesothelioma…

Biomarkers in Pleural Effusions Can Improve Mesothelioma Diagnosis
| | |

Biomarkers in Pleural Effusions Can Improve Mesothelioma Diagnosis

ByAlex Strauss

Italian scientists say some newly identified biomarkers in pleural effusions are very good at ruling out mesothelioma in patients who do not have the disease.  Unfortunately, most of these biomarkers are not as good as positively identifying mesothelioma. But their accuracy can be improved by combining several of them.  Pleural effusions are pockets of excess fluid that collect around the lungs of people with certain kinds of cancer and other conditions.  Mesothelioma biomarkers in pleural effusions are proteins and other substances that are mostly found in mesothelioma patients. The new study suggests that using these biomarkers the right way can lead to more accurate diagnoses. The Importance of Biomarkers in Pleural Effusions Pleural mesothelioma is a rare cancer of the…

New Prognostic Factor in Peritoneal Mesothelioma
|

New Prognostic Factor in Peritoneal Mesothelioma

ByAlex Strauss

Malignant peritoneal mesothelioma is a rare form of mesothelioma that attacks the membrane that lines the abdomen and surrounds internal organs. The outlook for this rare malignancy, which affects fewer than 500 Americans annually, has been improved by the treatment combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The combination has produced 5-year overall survival rates ranging from 29% to 63%. But not all peritoneal mesothelioma patients are good candidates for CRS/HIPEC. The challenge, for clinicians, is identifying which patients are likely to benefit from the procedure (or even be cured) and which are not. In an effort to help answer that question, French researchers recently tested the prognostic value of the glucose transporter protein GLUT1 as well as…